Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel T Milton

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Seminars in Oncology|July 1, 2005
Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancerDaniel T Milton, Vincent A Miller
Journal of Oncology Practice|September 3, 2011
ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in PracticeMary Beth Beasley, Daniel T Milton
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 24, 2004
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)Daniel T Milton, Mark G Kris, Jorge E Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Molecular on/off switchDaniel T Milton, Gregory J Riely, William Pao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancerJyoti D Patel, Thomas A Hensing, Alfred Rademaker, et al.
Cancer|April 22, 2005
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinibAntonio M P Omuro, Mark G Kris, Vincent A Miller, et al.
Clinical Colorectal Cancer|May 29, 2007
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-upChadi Nabhan, Avanthi Ragam, Brian Samuels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyVicki Leigh Keedy, Sarah Temin, Mark R Somerfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusGregory J Riely, Mark G Kris, Binsheng Zhao, et al.
Cancer|August 1, 2006
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancerDaniel T Milton, Christopher G Azzoli, Robert T Heelan, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|July 1, 2005
Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancerDaniel T Milton, Vincent A Miller
Journal of Oncology Practice|September 3, 2011
ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in PracticeMary Beth Beasley, Daniel T Milton
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 24, 2004
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)Daniel T Milton, Mark G Kris, Jorge E Gomez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Molecular on/off switchDaniel T Milton, Gregory J Riely, William Pao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancerJyoti D Patel, Thomas A Hensing, Alfred Rademaker, et al.
Cancer|April 22, 2005
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinibAntonio M P Omuro, Mark G Kris, Vincent A Miller, et al.
Clinical Colorectal Cancer|May 29, 2007
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-upChadi Nabhan, Avanthi Ragam, Brian Samuels, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyVicki Leigh Keedy, Sarah Temin, Mark R Somerfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2007
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusGregory J Riely, Mark G Kris, Binsheng Zhao, et al.
Cancer|August 1, 2006
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancerDaniel T Milton, Christopher G Azzoli, Robert T Heelan, et al.
Pageof 2